ProKidney Corp. (NASDAQ: PROK) has seen significant volatility following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study, which assesses rilparencel in patients suffering from ...
As of August 26, 2024, the average one-year price target for ProKidney is $4.76/share. The forecasts range from a low of $3.03 to a high of $6.30. The average price target represents an increase of 99 ...
Hosted on MSN
ProKidney Corp. (PROK) positioned to redefine chronic kidney disease treatment, believes HC Wainwright
ProKidney Corp. (NASDAQ:PROK) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, ProKidney Corp. (NASDAQ:PROK) has a “buy” rating from slightly more than half of the analysts ...
Rilparencel is ProKidney’s main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We’ll have Rilparencel’s Phase 2 full data in 2025, as ...
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...
ProKidney Corp. (NASDAQ:PROK) stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro. What happened: The ...
The average one-year price target for ProKidney (NasdaqCM:PROK) has been revised to $6.85 / share. This is an increase of 15.10% from the prior estimate of $5.95 dated December 3, 2025. The price ...
ProKidney Corp. (NASDAQ:PROK) is one of the hot penny stocks to invest in now. On July 15, JP Morgan analyst Anupam Rama maintained a neutral stance on ProKidney Corp. (NASDAQ:PROK), giving the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results